BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 7679090)

  • 1. Antibody-induced growth inhibition is mediated through immunochemically and functionally distinct epitopes on the extracellular domain of the c-erbB-2 (HER-2/neu) gene product p185.
    Xu F; Lupu R; Rodriguez GC; Whitaker RS; Boente MP; Berchuck A; Yu Y; DeSombre KA; Boyer CM; Bast RC
    Int J Cancer; 1993 Feb; 53(3):401-8. PubMed ID: 7679090
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The tyrosine kinase activity of the C-erbB-2 gene product (p185) is required for growth inhibition by anti-p185 antibodies but not for the cytotoxicity of an anti-p185-ricin-A chain immunotoxin.
    Xu FJ; Boyer CM; Bae DS; Wu S; Greenwald M; O'Briant K; Yu YH; Mills GB; Bast RC
    Int J Cancer; 1994 Oct; 59(2):242-7. PubMed ID: 7927925
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heregulin and agonistic anti-p185(c-erbB2) antibodies inhibit proliferation but increase invasiveness of breast cancer cells that overexpress p185(c-erbB2): increased invasiveness may contribute to poor prognosis.
    Xu FJ; Stack S; Boyer C; O'Briant K; Whitaker R; Mills GB; Yu YH; Bast RC
    Clin Cancer Res; 1997 Sep; 3(9):1629-34. PubMed ID: 9815853
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ligand-like effects induced by anti-c-erbB-2 antibodies do not correlate with and are not required for growth inhibition of human carcinoma cells.
    Shawver LK; Mann E; Elliger SS; Dugger TC; Arteaga CL
    Cancer Res; 1994 Mar; 54(5):1367-73. PubMed ID: 7907001
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relative cytotoxic activity of immunotoxins reactive with different epitopes on the extracellular domain of the c-erbB-2 (HER-2/neu) gene product p185.
    Boyer CM; Pusztai L; Wiener JR; Xu FJ; Dean GS; Bast BS; O'Briant KC; Greenwald M; DeSombre KA; Bast RC
    Int J Cancer; 1999 Aug; 82(4):525-31. PubMed ID: 10404066
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting multiple Her-2 epitopes with monoclonal antibodies results in improved antigrowth activity of a human breast cancer cell line in vitro and in vivo.
    Spiridon CI; Ghetie MA; Uhr J; Marches R; Li JL; Shen GL; Vitetta ES
    Clin Cancer Res; 2002 Jun; 8(6):1720-30. PubMed ID: 12060609
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monoclonal antibodies specific for the neu oncogene product directly mediate anti-tumor effects in vivo.
    Drebin JA; Link VC; Greene MI
    Oncogene; 1988 Apr; 2(4):387-94. PubMed ID: 2896329
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor-inhibitory monoclonal antibodies to the HER-2/Neu receptor induce differentiation of human breast cancer cells.
    Bacus SS; Stancovski I; Huberman E; Chin D; Hurwitz E; Mills GB; Ullrich A; Sela M; Yarden Y
    Cancer Res; 1992 May; 52(9):2580-9. PubMed ID: 1373672
    [TBL] [Abstract][Full Text] [Related]  

  • 9. p185(neu) protein is required for tumor and anchorage-independent growth, not for cell proliferation of transgenic mammary carcinoma.
    Nanni P; Pupa SM; Nicoletti G; De Giovanni C; Landuzzi L; Rossi I; Astolfi A; Ricci C; De Vecchi R; Invernizzi AM; Di Carlo E; Musiani P; Forni G; Menard S; Lollini PL
    Int J Cancer; 2000 Jul; 87(2):186-94. PubMed ID: 10861472
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rat MAbs to the product of the c-erbB-2 proto-oncogene for diagnosis and therapy in breast cancer.
    Dean CJ; Eccles SA; Valeri M; Box G; Allan S; McFarlane C; Sandle J; Styles J
    Cell Biophys; 1993; 22(1-3):111-27. PubMed ID: 7534210
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Both the epitope specificity and isotype are important in the antitumor effect of monoclonal antibodies against Her-2/neu antigen.
    Kim KM; Shin EY; Moon JH; Heo TH; Lee JY; Chung Y; Lee YJ; Cho HM; Shin SU; Kang CY
    Int J Cancer; 2002 Dec; 102(4):428-34. PubMed ID: 12402315
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Suppression of diacylglycerol levels by antibodies reactive with the c-erbB-2 (HER-2/neu) gene product p185c-erbB-2 in breast and ovarian cancer cell lines.
    Boente MP; Berchuck A; Whitaker RS; Kalén A; Xu FJ; Clarke-Pearson DL; Bell RM; Bast RC
    Gynecol Oncol; 1998 Jul; 70(1):49-55. PubMed ID: 9698473
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radiolabeled antibody targeting of the HER-2/neu oncoprotein.
    De Santes K; Slamon D; Anderson SK; Shepard M; Fendly B; Maneval D; Press O
    Cancer Res; 1992 Apr; 52(7):1916-23. PubMed ID: 1348016
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies.
    Drebin JA; Link VC; Stern DF; Weinberg RA; Greene MI
    Cell; 1985 Jul; 41(3):697-706. PubMed ID: 2860972
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Requirements for the internalization of a murine monoclonal antibody directed against the HER-2/neu gene product c-erbB-2.
    Maier LA; Xu FJ; Hester S; Boyer CM; McKenzie S; Bruskin AM; Argon Y; Bast RC
    Cancer Res; 1991 Oct; 51(19):5361-9. PubMed ID: 1680547
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The extracellular domain of p185/neu is released from the surface of human breast carcinoma cells, SK-BR-3.
    Zabrecky JR; Lam T; McKenzie SJ; Carney W
    J Biol Chem; 1991 Jan; 266(3):1716-20. PubMed ID: 1671042
    [TBL] [Abstract][Full Text] [Related]  

  • 17. p185 HER2/neu epitope mapping with murine monoclonal antibodies.
    Centis F; Tagliabue E; Uppugunduri S; Pellegrini R; Martignone S; Mastroianni A; Ménard S; Colnaghi MI
    Hybridoma; 1992 Jun; 11(3):267-76. PubMed ID: 1379973
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of the p185 encoded by HER2 oncogene in normal and transformed human tissues.
    Natali PG; Nicotra MR; Bigotti A; Venturo I; Slamon DJ; Fendly BM; Ullrich A
    Int J Cancer; 1990 Mar; 45(3):457-61. PubMed ID: 1968437
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of tumor cell growth by antibodies induced after vaccination with peptides derived from the extracellular domain of Her-2/neu.
    Jasinska J; Wagner S; Radauer C; Sedivy R; Brodowicz T; Wiltschke C; Breiteneder H; Pehamberger H; Scheiner O; Wiedermann U; Zielinski CC
    Int J Cancer; 2003 Dec; 107(6):976-83. PubMed ID: 14601058
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diminution of antibodies directed against tumor cell surface epitopes: a single chain Fv fusion molecule specifically recognizes the extracellular domain of the c-erbB-2 receptor.
    Wels W; Harwerth IM; Hynes NE; Groner B
    J Steroid Biochem Mol Biol; 1992 Sep; 43(1-3):1-7. PubMed ID: 1381944
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.